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PENGARUH PENGEKSPRESAN GEN TERT, AKTIVITI 
TELOMERASE DAN PANJANGAN TELOMERE  TERHADAP 
KERINTANGAN IMATINIB MESYLATE DALAM PESAKIT LEUKEMIA 
MIELOID KRONIK DI MALAYSIA 
ABSTRAK 
Leukemia mieloid kronik adalah neoplasma myeloproliferatif yang 
didiagnosa dengan kehadiran gen gabungan BCR-ABL yang menghasilkan tirosin 
kinase yang memberikan isyarat proliferasi sel darah putih. Pengenalan imatinib 
mesylate pada awal tahun 2000, telah meningkatkan kelangsungan hidup pesakit 
yang terjejas dan mengubah pengurusan penyakit secara dramatik. Walau 
bagaimanapun, kegagalan membasmi sel-sel leukaemia sepenuhnya dan pelepasan 
sel-sel ini dari kawalan sebelumnya telah menyebabkan pencarian secara intensif 
dijalankan bagi mekanisme rintangan dan rawatan seterusnya untuk mengatasi 
rintangan ini. Sementara itu, pengawalaturan telomerase dan penyelenggaraan 
telomere adalah faktor penting dalam percambahan sel dan kelangsungan hidup yang 
memainkan peranan penting dalam perkembangan kanser. Anggapan bahawa 
telomerase sebagai komponen penting dalam pengawalaturan sel, ia mungkin 
merupakan salah satu mekanisme tercetusnya kanser dalam penghasilan CML dan 
mungkin juga menyumbang dalam mekanisme rintangan terhadap rawatan imatinib 
mesylate. Sebanyak 98 pesakit CML direkrut dari empat hospital yang bekerjasama 
di seluruh negara iaitu Hospital Pulau Pinang, Hospital Sultanah Aminah, Hospital 
Raja Permaisuri Bainun dan Pusat Perubatan Universiti Kebangsaan Malaysia. 
Sampel juga dikumpul dari Hospital USM yang merupakan pusat penyelidikan bagi 
xxii 
kajian ini. Pesakit CML yang dirawat dengan imatinib mesylate dibahagikan kepada 
2 kumpulan iaitu kumpulan yang memberi respon yang baik tehadap rawatan dan 
kumpulan yang rintang terhadap rawatan. Pada awal pengumpulan sampel, seramai  
enam puluh enam pesakit terdiri daripada kumpulan yang memberikan respon baik 
dan 32 pesakit bagi kumpulan yang rintang telah berjaya direkrut. Walau 
bagaimanapun, 90 sampel dapat diekstrak DNA dan RNA sementara hanya 79 
sampel sahaja berjaya digunakan untuk pengekstrakan protein kerana kualiti sampel 
yang diperoleh tidak baik. Umur pesakit yang terlibat dalam kajian ini adalah antara 
71 hingga 77 tahun dan merupakan etnik utama di Malaysia yang terdiri daripada 
kaum Melayu, Cina dan India. Analisis tahap ekspresi hTERT, aktiviti telomerase 
dan panjang telomere pada sampel telah dilakukan. Tahap ekspresi meningkat dan 
kehadiran aktiviti telomerase dijumpai dalam 90% daripada jumlah keseluruhan 
pesakit CML dalam kajian ini tanpa mengambikira perbezaan terhadap kumpulan 
tindakbalas terhadap rawatan menunjukkan kawalatur telomerase sebangai petunjuk 
kejadian kanser dalam CML. Walaubagaiman pun, perbandingan antara kumpulan 
tindakbalas berbeza terhadap rawatan imatinib mesylate tidak menunjukkan sebarang 
perbezaan yang signifikan (p=0.463 dalam pengekspresan hTERT dan p=0.961 
dalam aktiviti telomerase). Perbandingan panjang telomere dalam kedua dua 
kumpulan juga tidak menunjukkan perbezaan yang signifikasi (p=0.228). Hasil 
kajian menunjukkan pengekspresan hTERT, aktiviti telomerase dan panjang telomere 
berkemungkinan tidak memberi pengaruh secara langsung terhadap kerintangan 
kepada rawatan imatinib mesylate. Sehingga kini, masih tiada kajian perbandingan 
berkaitan tahap pengekspresan dan aktiviti telomerase dalam kumpulan pesakit 
dengan tondakbalas berbeza terhadap rawatan yang diberi. Daripada kajian ini juga 
dapat dianggapkan bahawa pengekspresan hTERT dan telomerase aktiviti berserta 
xxiii 
panjang telomere mungkin mempunyai pengaruh lain dalam perbezaan kesan 
kerintangan berbanding kanser lain. Kajian lanjutan dengan saiz sampel yang lebih 
besar diperlukan untuk mengesahkan potensi pengaruh komponen telomerase dan 
telomere dalam leukemogenesis dan kerintangan terhadap imatinib pada pesakit 






















INFLUENCE OF TERT GENE EXPRESSION, TELOMERASE 
ACTIVITY AND TELOMERE LENGTH IN RELATION TO IMATINIB 
MESYLATE RESISTANCE IN MALAYSIAN CHRONIC MYELOID 
LEUKAEMIA PATIENTS 
ABSTRACT 
Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm 
diagnosed by the presence of the BCR-ABL fusion gene which  produces a tyrosine 
kinase to signal a proliferation of white blood cells. The introduction of imatinib 
mesylate in early 2000, has dramatically increased the survival of affected patients 
and changed the disease management. However, failure to completely eradicate 
leukaemic cells and the escape of these cells from previous control has led to an 
intensive search for the mechanisms of resistance and subsequent treatments by 
which to overcome the resistance. Meanwhile, telomerase regulation and telomere 
maintenance are the critical factors in cell proliferation and survival which plays 
important roles in development of cancers. Considering telomerase as an important 
component in cell regulations, it is postulated that telomerase might be one of the 
oncogenesis mechanism in CML development and might contribute in the resistance 
mechanism of imatinib mesylate. A total of 98 CML patients were recruited from 
four collaborated hospitals over the country which are Hospital Pulau Pinang, 
Hospital Sultanah Aminah, Hospital Raja Permaisuri Bainun and Pusat Perubatan 
Universiti Kebangsaan Malaysia. Samples were also collected from Hospital USM 
which is the research center for this study. CML patients treated with imatinib were 
enrolled into this study and grouped as good response and resistance according to 
response of the imatinib mesylate treatment. Sixty-six of patients with good response 
xxv 
at the beginning of samples collection and 32 patients with resistance response were 
managed to recruited. However, only 90 samples were able to proceed with DNA 
and RNA extraction while 79 samples were successfully applied for protein 
extraction due to poor quality of samples obtained. Range of age was between 71 to 
77 years old and represented of main ethnicity in Malaysia which were Malay, 
Chinese and Indian. The analysis of hTERT expression level, telomerase activity and 
length of telomere were performed. The up regulated of hTERT expression and the 
presence of telomerase activity were found up to 90% in CML patients recruited in 
this study regardless of response group. This indicated that telomerase regulations as 
the indicator of cancer events in CML. However the telomerase regulations might not 
directly influenced the response and resistance group of treated patients.  
Comparison between good response and resistance group showed no significant 
difference (p=0.463 in hTERT expression and and p=0.961 in telomerase activity). 
Comparison of telomere length in both groups were also showed no significant 
difference (p=0.228). The findings indicated that hTERT expression, telomerase 
activity and telomere length may not directly influnced the resistance to imatinib 
mesylate treatment. To the best of our knowledge, there is no study comparing the 
expression and activity of telomerase in group of difference response to imatinib 
treatment in CML patients. This could consider that hTERT and the activitiy of 
telomerese together with telomere length in CML might have different contributions 
in resistance development compared to other solid tumours. Further more, 
investigations with a larger number of samples is warranted to confirm the potential 
influence of the telomerase and telomere components in the leukaemogenesis and 
imatinib resistance in Malaysian CML patients. 
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CHAPTER 1  
 
INTRODUCTION 
1.1 Research background 
Cancer is a malignant growth that can spread to almost any part of the body. 
The growths often attack surrounding tissue and potentially metastasize to other parts 
of body. Early detected cancers might be cured by medical procedure such as 
surgery, radiotherapy or chemotherapy. Nowadays cancers are responsible for the 
majority of global death. According to World Health Organization (WHO), cancer is 
the second leading cause of death globally and responsible for an estimated 9.6 
million deaths in 2018 with 18.1 million of cases and expected to reach 2.4 million 
cases in 2040 (WHO, 2020). Global Cancer Statistics 2018 reported that three 
leading cause of cancer death are lung cancer as the most frequent followed by 
female breast cancer and prostate cancer (Bray et al., 2018). The formation and 
development of cancer is caused by the accumulation of genetic mutations in cells. 
An increasing life expectancy extends the period over which oncogenes act on cells 
and increases the risk of cancer development.  
In Malaysia, report on incidence of cancer cases was latest updated for the 
year period of 2012-2016 by Malaysia National Cancer Registry (MNCR). A total of 
115,238 cancer cases were diagnosed during that period. Three most common 
cancers among Malaysian residents were breast cancer followed by colorectal and 
lung. Of these 51,505 (44.7%) were reported in males and 63,733 (55.3%) in 
females. The most common cancer among male and female residents was colorectal 
(14.8 in 100,000) and breast (34.1 in 100,000) respectively. Leukaemia is among ten 
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most common cancer in Malaysia (Table 1.1) being the seventh most common in 

























Table 1.1Number of cases in most common cancers in Malaysia.  
Types of cancer Number of cases (%) 
Breast  
Colorectal  




















Total Number 115,238 (100.0) 













1.2 Problem statement  
Chronic myeloid leukaemia is characterized by the presence of Philadephia 
(Ph) chromosome which occurs from the fusion of Abelson (ABL) gene on the 
chromosome 9 with the break-point cluster region (BCR) gene on chromosome 22. 
This results in expression of hybrid protein termed BCR-ABL1; a constitutively 
active tyrosine kinase that gives signal for the production of unregulated cell division 
thus contributing to leukaemogenesis. Starting 2001, United States Food and Drug 
Administration (US FDA) has proven the use of imatinib mesylate as first-line 
treatment to CML patients (Cohen et al., 2002). Imatinib is an orally administered 
protein-tyrosine kinase inhibitor of the BCR-ABL protein tyrosine kinase which 
blocks proliferation and induces apoptosis of BCR-ABL1. Since the year of 
introduction of imatinib mesylate, the annual mortality in CML has decreased from 
10-20% down to 1-2% (Huang, Cortes & Kantarjian, 2012). Therefore, imatinib 
mesylate has unquestionably revolutionized the therapy of CML by lowering the 
rates and duration of remission of the disease. However, there was still a subset of 
patients who developed suboptimal response or fail to response upon this treatment. 
Drug resistance in this disease remains a major problem and raised up clinical 





1.3 Rationale of the study 
The emergence of imatinib resistance in CML patients highlights the 
importance of understanding the molecular mechanisms associated with imatinib  
mesylate resistance. The molecular mechanisms implicated in this resistance include 
those that involve upregulation or mutation of BCR-ABL1 kinase and those that are 
BCR-ABL1 independent. The BCR-ABL1 dependent is generally associated with 
point mutations in ABL-kinase domain which is the main reason for imatinib 
resistance in CML. While in BCR-ABL1 independent, the BCR-ABL1 tyrosine 
kinase remains inhibited by imatinib mesylate, but there might be post-translational 
activation of another key enzyme such as telomerase that activates alternative 
signalling pathways leading to uncontrolled cell growth.  
In this study, we focused on the BCR-ABL1 independent mechanism in 
particular, factors related with telomerase in the resistance of imatinib mesylate 
treatment. Accessing the telomerase expression and activity together with the length 
of telomere in CML patients treated with imatinib might give better understanding on 








1.4 Research hypotheses 
 
1. There will be higher expression of hTERT and relatively higher frequency 
of patients with telomerase activity in resistance group of patients 
compare with good response group. 
2. There will be higher telomerase activity in resistance group of patients  




1.5 Research questions 
1. Is hTERT expression level different and relatively higher in resistance 
group of CML patients? 
2. Is telomerase  activity different and relatively higher in resistance group 
of CML patients? 













This study focused on hTERT expression and telomere length in chronic myeloid 
leukaemia patients and the potential activation of telomerase among treated patients 




1. To determine the expression profile of hTERT in good response and resistance 
chronic myeloid leukaemia patients treated with imatinib mesylate. 
2. To identify the telomerase activity in good response and resistance chronic 
myeloid leukaemia patients treated with imatinib mesylate. 
3. To measure the average telomere length in good response and resistance chronic 
myeloid leukaemia patients treated with imatinib mesylate.  
4. To associate the hTERT expression level, telomerase activity and telomere length 
with clinical and demographic data of both groups of patients response and 
resistance to imatinib mesylate treatment. 
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CHAPTER 2 LITERATURE REVIEW 
2.1 Hematological malignancies 
Hematological malignancies are cancers that affect blood, bone marrow 
and/or lymph nodes. The pluripotent hematopeitic stem cells in bone marrow mature 
and differentiate into 3 types of blood cells; white blood cells, red blood cells and 
platelets. White blood cells are mainly fight for infection, red blood cells facilitate 
tissue oxygenation while platelets are to maintain the integrity of vascular system 
and blood clotting.  The disruption of normal differentiation in hematopoietic stem 
cells causes the hematological malignancies. The resulting disease depends on how 
mutations affect the differentiation pathway of the stem cells. Hematological 
malignancies includes multiple myelomas, lymphomas (Hodgkin‘s and non-
Hodgkin‘s) and various type of leukaemias. 
2.2 Leukaemia 
There are four major types of leukaemias; acute lymphocytic leukaemia 
(ALL), acute myeloid leukaemia (AML), chronic lymphocytic leukaemia (CLL) and 
chronic myeloid leukaemia (CML). Leukaemias are generally categorized into acute 
or chronic based on the percentage of blast cells in bone marrow or blood. The acute 
and chronic forms differ in cell maturity on onset. In acute leukaemias, the number 
of immature blood cells are rapidly increased. The crowding that results from such 
cells causes the bone marrow to be unable to produce healthy blood cells. Later, 
resulting in low production of hemoglobin and platelets in the body. Rapid 
progression and accumulation of the malignant cells could spills over into the 
peripheral blood and spread to other organs of the body. Therefore, an immediate 
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treatment is required in acute leukaemias. Acute forms may occur in both adults and 
children  but most common in children.  
Chronic leukaemias are distinguished from acute leukaemias by the slower 
progression with matured abnormal cells. Normal cell production may occurs as well 
for a long period of time but later in late stages of chronic disease, the abnormal cells 
interfere with normal cell productions. The abnormal cells eventually suppress the 
production of normal white blood cells causes the body to expose on infection. Onset 
for chronic is much slower that normally over months or years. Chronic forms 
mostly occurs in older people and rare in children (de la Fuente et al., 2014). The 
acute and chronic  leukaemias are divided into myeloid or lymphoid based on the 
lineage of the blast cells. 
The biological centrum of leukaemia is the formation and development of 
blood cells called hematopoeisis. All blood cells are derived from hematopoeitic 
stem cells which are produced in bone marrow. These cells can self-renew and 
differentiate into precursor called myeloid and lymphoid lineages. The myeloid 
lineages lead to the mature fully differentiated cells including megakaryocyte, which 
form thrombocytes, erythrocytes and various of granulocytes (eosinofil, basofil, 
neutrophil and monocytes). The matured lymphoid lineages of hematopoeisis form 
B-lymphocytes, T-lymphocytes and natural killer cell (Figure 2.1). 
The classification of leukaemia is according to World Health Organization 
(WHO) and French-American-British (FAB) system. The WHO classification is 
based on a combination of clinical, morphologic, immunophenotypic, and genetic 
features (Arber et al., 2016). The FAB system is less commonly used and the 
classification is based on the morphology of the abnormal leukocytes. 
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 Higher numbers of immature white blood cells in leukaemia patients result in 
lack of blood platelets and easily become bruised, excessively bleed or develop 
petechiae. Suppressed or dysfunctional white blood cells cause the patient's immune 
system to unable to fight off even a mild infection. Some patients experience 
frequent infection ranging from infected tonsils, sores in the mouth or diarrhea to 
life-threatening pneumonia or opportunistic infections. The red blood cell deficiency 
leads to anemia. Some patients experience other symptoms such as night sweats, 
chills, feeling sick, fatigue, having fever, nausea or a feeling of fullness due to an 
enlarged liver and spleen. 
 Several risk factors have been identified for leukaemia including ionizing 
radiation and exposure to chemotherapeutic drugs or chemical such as benzene 
(Bloemen et al., 2004). Risk of developing leukaemia is increased in patients with 
history of autologous stem cell transplantation. Like other cancers, leukaemia results 
from somatic mutations in the DNA. Therefore, activating oncogenes or deactivating 
tumor suppressor genes can cause distruption in differentiation or regulation of cell 
death. The use of tobacco is also associated with a small increase in the risk of 
developing acute myeloid leukaemia in adults (Fircanis et al., 2014). Cohort and 
case-control studies have linked exposure to some petrochemicals and hair dyes to 
the development of some forms of leukaemia (Clapp, Jacobs & Loechler, 2008). A 
few cases of maternal-fetal transmission have also been reported (Hassanzadeh et al., 
2011). Diet has very limited or no effect, although eating more vegetables may 
confer a small protective benefit. Viruses have also been linked to some forms of 
leukaemia. Experiments on mice and other mammals have demonstrated the 
relevance of retroviruses in leukaemia, and human retroviruses have also been 




Figure 2.1 Diagram shows hematopoetic stem cells differentiation. The blood stem 
cells differentiate into pluripotent stem cells which are lymphoid lineage and myeloid 
lineage. The myeloid stem cell then differentiates into red blood cells, or a type of 
white blood cell, a neutrophil while the lymphoid stem cell differentiates into T cells, 










2.3 Chronic myeloid leukaemia 
 
 Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm 
characterized by dysregulated production and uncontrolled proliferation of mature 
and maturing granulocytes in the bone marrow. CML accounts for 15–20% of all 
cases of leukaemia in adults (Soverini et al., 2016). Clinically, peripheral blood cell 
profile shows an increased number of granulocytes and blast cells. Patients are often 
asymptomatic at the early stage with onset of nonspecific symptoms such as 
fatigue, weakness, anorexia, weight loss, night sweats, a sense of abdominal 
fullness, gouty arthritis and symptoms of leucostasis which may prompt evaluation. 
CML is a slow progressing white blood cancer of myeloid cell lineage. There 
is an elevated white blood cell count including granulocytes especially neutrophils. 
Other than chronic myeloid leukaemia, CML also known as chronic myelogenous 
leukaemia, chronic myelocytic leukaemia or chronic granulocytic leukaemia. CML is 
the third most common type of leukaemia. Currently CML is treated with imatinib 
mesylate as a standard first-line  treatment.  
 
2.3.1 Molecular pathogenesis of chronic myeloid leukaemia 
Philadephia chromosome discovered by Nowell and Hungerford in 1960 is 
the hallmark of genetic abnormality in CML. It was named after the city it was 
discovered. Peter Nowell was an investigative pathologist in the Department of 
Pathology at the University of Pennsylvania, and David Hungerford was a 
cytogeneticist at the Institute for Cancer Research in Philadelphia. They found a 
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short chromosome in patients with granulocytic leukaemia and speculated a direct 
involvement of this truncated chromosome in the genesis of the disease (Nowell, 
1962). This was the first proof that the disease results in some changes to DNA. 
After the establishment of chromosomal banding techniques, shortened chromosome 
22 resulting from a reciprocal translocation of chromosome 9 and 22 were explained 
by Janet Rowley and known as Philadephia positive (Ph+) (Rowley, 1973) (Mughal 
et al., 2016).  
Majority of CML patients (90-95%) exhibited this abnormality. However, the 
Philadelphia translocation is not specific for CML since it can also be detected in 
other entities. It was observed in 11-29% of acute lymphoid leukaemia (ALL) 
patients (Pullarkat et al., 2008) and relatively rare in acute myeloid leukaemia 
(AML) patients with less than 1.5% (Soupir et al., 2007). To date, the mechanism of 
this single aberration that give results in different clinical phenotypes is still not well 
understood (Mughal et al., 2016).  
The shortened chromosome 22 at band q11.21 and elongated chromosome 9 
at band q34.1 was referred as t(9;22)(q34;q11) (Goldman, 2008). The translocation 
involved a large segment of Abelson (ABL) proto-oncogene from the long arm of 
chromosome 9 and the breakpoint cluster region (BCR) genes on the long arm of 
chromosome 22 producing a fusion gene, BCR-ABL1 (Goldman and Mughal, 2005) 
(Figure 2.1).  
 The BCR gene spans 130 kb, contains 23 exons (Miller et al., 1988) and 
situated closer to the centromere (Heisterkamp et al., 1985). It is widely expressed in 
a wide variety of actively proliferating and nonproliferating vertebrate tissues 
(Collins, Coleman & Groudine, 1987). In chick embryos, as well as in mouse and 
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human tissues, BCR mRNA levels were found to be highest in the brain and 
hematopoietic cells (Zhu, Heisterkamp & Groffen, 1990). The gene represents a 
serine or threonine kinase consisting among others of a coiled-coil oligomerization 
domain and influences different signalling pathways via interaction with partners 
such as growth factor receptor bound protein 2 (GRB2) or ABL1 (Ren, 2005). 
 ABL1 gene, located on chromosome 9 is an oncogene that changes the 
activity of other proteins by adding a cluster of oxygen and phosphorus atoms 
(Szczylik et al., 1991). It is a member of the non-receptor tyrosine kinase family that 
transduces signals from growth factor and adhesion receptors from the cell surface to 
the nucleus (Hernández et al., 2004). The native ABL kinase has tightly regulated 
kinase activity and located in the nucleus while the mutated gene encodes a protein 
containing a tyrosine kinase activity domain (SH1) in addition to two other 
regulatory domains (SH2 and SH3) that mediates protein-protein interaction and 
modulate activation of signal transduction (Vigneri & Wang, 2001). The ABL1 
kinase is normally inactive and should be activated to perform its functions. The 
kinase can be activated by a number of different triggers by adding a phosphate 
group to other different proteins. The diversity allows ABL1 to be involved in a wide 
variety of cellular processes including cell proliferation, differentiation and migration 
(Deininger et al., 2005).  
 The BCR-ABL fusion protein is located in the cytoplasm and has a 
constitutively activated tyrosine kinase. This chimeric gene functions by binding to 
ATP and transfers phosphate from ATP to tyrosine residues, activating multiple 
signal transduction pathways . This event causes excessive cellular proliferation, 
prevention of apoptosis, and decreasing cellular adhesion. It has been shown that the 
enhanced tyrosine kinase activity of BCR-ABL1 chimeric protein is essential for the 
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pathogenesis and the expression of this aberrant transcript is likely to represent the 
initiating event of CML (Sawyers Charles L, 1999).  
Due to varying breakpoints of BCR-ABL1 transcripts containing different exons of 
ABL1 and BCR, proteins with molecular weights of 190 kDa, 210 kDa, and 230 kDa 
were translated. The three types of breakpoint in the BCR-ABL region are Major 
breakpoint cluster region (M-bcr), minor breakpoint cluster region (m-bcr) and micro 
breakpoint cluster region (μ-bcr). M-bcr is commonly found within 5.8kb region, 
spanning approximately 5 exons and it encodes a fusion protein called p210 BCR-
ABL fusion protein (Melo, 1997). Minor breakpoint  cluster region (m-bcr) is 
detected in two-third of Ph-positive ALL and in rare cases of CML which spans in 
the long intron (54.4kb) (Chissoe et al., 1995) and translated into a smaller fusion 
protein of 190 kDa (p190BCR-ABL). Micro breakpoint cluster region (μ-bcr) is 
translated into p230 BCR-ABL fusion gene (Melo, 1997). This p230BCR-ABL has 
additional of 180 amino acids encoded by 540 bp of extra sequence  of BCR as 
compared to the classic p210BCR-ABL. All these three type of breakpoints have 








Figure 2.2 Ilustration of Philadephia chromosome formation resulting from 
reciprocal translocation events between chomosome 9 and 22 which carries the BCR-
ABL fusion gene [Adapted from (Ali, 2016)]. 
 
 







2.3.2 Diagnosis and classification of chronic myeloid leukaemia 
Chronic myeloid leukaemia normally suspected based on an abnormal complete 
blood count (CBC) obtained incidentally or during evaluation of splenomegaly. A 
CBC shows the number of different kinds of cells in the blood and is often done as 
part of a regular medical checkup. The granulocyte count is elevated, 
usually ≤50×109/L in asymptomatic patients and 200×109/L to 1,000×109/L in 
symptomatic patients. Neutrophilia, basophilia, and eosinophilia are common. The 
platelet count is normal or moderately increased, and in some patients, 
thrombocytosis is the presenting manifestation. The hemoglobin level is 
usually more than 100 g/L. To differentiate CML from leukocytosis of other 
etiology, peripheral smear is needed. In CML, the peripheral smear frequently 
shows immature granulocytes as well as absolute eosinophilia and basophilia. 
However, in patients with white blood cell counts ≤50×109/L and even in some 
with higher white blood cell counts, immature granulocytes may not be seen. Bone 
marrow examination should be done to confirm the diagnosis of CML by 
cytogenetic or molecular analysis. However, the absent of Philadephia abnormality 
in 5% of CML patients could be confirmed by fluorescence in situ hybridization 
(FISH) or reverse transcription polymerase chain reaction (RT-PCR).  
In defining the disease entities of clinical significance, criteria revised by 
WHO includes clinical features, morphology, immunophenotyping, cytogenetics, and 
molecular genetics. These criterias which derived from numerous published clinical 
and scientific studies from the experience of more than 100 worldwide pathologists, 
hematologists, oncologists, geneticists and clinicians were regularly updated for the 
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improvement of the diagnostic criteria as well as the prognostic relevance of current 
entities (Arber et al., 2016).   
2.3.3 Clinical phases and stages in CML 
 The next stage of diagnosis is to determine the phase of the disease. Most 
patients at the point of diagnosis are in a chronic phase (CP). However, there are also 
patients who are diagnosed with an acceleration phase (AP) or a blastic phase (BP). 
Determination of the phase of the disease is important for the appropriate treatment 
option. There are triphasic clinical phases of CML which are chronic, accelerate and 
blastic. In Sweden, the WHO classifications are mainly used while the European 
LeukaemiaNet (ELN) classifications are used in most clinical studies. The diagnostic 
criteria are summarized in Table 2.1. Since WHO recognizes the practical 
importance of the blast count in categorizing myeloid diseases and in predicting 
prognosis, the phases are based mainly on the number of blast cells in the blood or 
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2.3.3(a) Chronic phase 
Chronic phase is the earliest phase of CML. Patients in the chronic phase 
typically have less than 10% blasts in their blood or bone marrow samples 
(Vardiman et al., 2014). Most patients were diagnosed in the chronic phase with 85% 
of patients are asymptomatic. Diagnosis is usually incidentally when the patient has a 
full blood count or peripheral blood smear showing an elevated white blood count 
including basophilia or platelet. A bone marrow aspiration is then needed for further 
confirmation. Patients with chronic phase may have fatigue, weight loss, low-grade 
fever, loss of energy, decreased exercise tolerance and excessive sweating due to 
hypermetabolism. Elevated white blood cell count or splenomegaly found on routine 
assessment. Others such as early satiety and decreased food intake from 
encroachment on stomach by enlarged spleen.  
The chronic phase is usually relatively stable and benign phase of CML and 
generally lasts for 3–5 years from diagnosis. During this period, malignant progenitor 
cells proliferate rapidly but retain their ability to differentiate. Progression of CML is 





2.3.3(b) Accelerated phase 
Patients who do not response well to treatment during their chronic phase are 
prone to develop cancer that are more aggressive with noticeable symptoms which is 
accelerated phase. The accelerated phase is diagnosed in the presence 10-19% blast 
in peripheral blood or bone marrow. The criteria for accelerated phase by WHO has 
been revised in 2016 with the additional of reponse to tyrosine kinase inhibitor 
instead of hematologic or cytogenetic criterias (Table 2.2) (Arber et al., 2016). In 
comparison with the previous editions of the WHO classification, new parameter is 
the presence of which justifies the diagnosis of AP. These include the persistent 
leukocytosis (10×109/L) not responding to treatment, persistent splenomegaly not 
responding to treatment and additional clonal chromosomal aberrations in Ph+ cells 
present at the point of diagnosis. Despite these changes, the criterias are still differ 
significantly to those described by  European LeukaemiaNet (ELN) guidelines, 
International Bone Marrow Transplant Registry and MD Anderson Cancer Center 
(MDACC). According to WHO, the AP should be diagnosed in the presence of blasts 
in the bone marrow or peripheral blood at a percentage of 10%–19%, while 
according to ELN this range is higher which is 15%-29%. 
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2.3.3(c) Blastic phase 
The most aggressive stage of CML is blastic phase. The definition of blastic 
phase is slightly simpler, when the percentage of blasts in the peripheral blood or 
bone marrow is 30% or more according to ELN and 20% or more according to 
WHO. It is also diagnose with the case of extramedullary blast proliferation (Flis & 
Chojnacki, 2019). At this stage, haematopoietic differentiation has become arrested 
and immature blasts accumulate in the bone marrow and spill into the circulation 
system. Symptoms are similar to those of acute myeloid leukaemia. The blast phase 
is usually fatal within 3–6 months of onset. Transition between the phases may be 
gradual or rapid. Typically, the annual progression from chronic to blast phase is 5–
10% in the first 2 years and 20% in subsequent years (Vardiman et al., 2014). During 
this crisis, almost 80% of patients are observed with additional chromosomal 
abnormalities such as double Ph chromosome, trisomy 8, trisomy 19, i(17q) and also 
loss of rearrangment involving 11p (Barnes & Melo, 2002).  
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2.3.4 Epidemiology 
In Western countries, population-based registries such as Surveilance, 
Epidemiology and End Results (SEER), Leukaemia Research Fund, British 
Haematological Malignancy Research Network (HMRN), European Treatment and 
Outcome Study (EUTOS), Swedish CML Registry has been established in detailed 
the data collection on demographics epidemiology of chronic myeloid leukaemia at 
regional or national level. CML in Western countries accounts for 15–25% of all 
adult leukaemias and 14% of leukaemias overall including the pediatric population . 
The incidence was reported between 0.4-2 cases per 100,000 per year while the 
prevalence expected between 3-15 cases per 100,000 in 2017. The median age of 
CML was between 57–60 years and a male to female ratio was 1.2–1.7. (Tadwalkar, 
2017), (Noone et al., 2017).  
To date, global prevalence of CML was seen increasing with approximately 
10-12 per 100,000 per year affecting subjects of all age groups. This steadily 
increasing number was due to prolongation of survival in patients that has been 
achieved with the efficacy of tyrosine kinase inhibitors as targeted therapy in treating 
the disease (Höglund, Sandin & Simonsson, 2015), (Rohrbacher & Hasford, 2009).  
In Asia, incidence of CML reported lower (0.-2.2 per 100,000 population)  
than in Western countries with median age at diagnosis within range of 37-55 years 
old (Au et al., 2009). Data on incidence and prevalence of CML in Malaysia was 
very limited and currently only reported for the area of Southern Sarawak with the 
incidence of 0.8 per 100,000 population per year for the year 2011-2016 and 
estimated prevalence of 6.9 per 100,000 population at the year 2016. Median age of 
